(379 days)
The Rightest Blood Glucose Monitoring System GM700 is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole samples drawn from the fingertips, palm and forearm. The Rightest Blood Glucose Monitoring System GM700 is intended to be used by a single person and should not be shared.
The Rightest Blood Glucose Monitoring System GM700 is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The Rightest Blood Glucose Monitoring System GM700 should not be used for the diagnosis of, or screening for diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).
The Rightest Blood Glucose Test Strip GS700 is for use with the Rightest Blood Glucose meter GM700 to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip, palm or forearm.
The Rightest Control Solution GC700 is for use with the Rightest Blood Glucose meter GM700 and Rightest Blood Glucose Test Strips GS700 to check that the meters and test strip are working together properly and that the test is performing correctly.
Our Rightest Blood Glucose Monitoring System GM700 consists of the following devices: Rightest Blood Glucose Meter GM700, Rightest Blood Glucose Test Strip GS700, Rightest Control Solution GC700, lancing device and sterile lancets. The Rightest Blood Glucose Meter GM700, Rightest Blood Glucose Test Strips GS700, and Lancing Device are manufactured by BIONIME Corporation. The Rightest Blood Glucose Meter GM700, when used with the Rightest Blood Glucose Test Strips GS700, quantitatively measures glucose in fresh capillary whole blood. The Rightest Blood Glucose Monitoring System GM700 is verified by the Rightest Control Solution GC700.
A Rightest Blood Glucose Monitoring System GM700 kit box may contain different bundled items.
Here's a summary of the acceptance criteria and study information for the Rightest Blood Glucose Monitoring System GM700, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
The provided text only explicitly states that the device "met the acceptance criteria" for the system accuracy study. It does not numerically list the specific acceptance criteria for blood glucose monitoring systems, nor does it provide a direct numerical performance result. In the absence of a detailed table from the source, I will indicate the general finding.
| Metric (Implied) | Acceptance Criteria (Not explicitly stated in text but generally understood for BGMS) | Reported Device Performance |
|---|---|---|
| System Accuracy | (General criteria for blood glucose monitoring systems, not provided in this text) | Met the acceptance criteria |
| User Performance | (Criteria for lay user accuracy, not provided in this text) | Lay consumers could obtain accurate results |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Accuracy Study: 103 patients
- Sample Size for User Performance Study: Not explicitly stated, but implies a sufficient number of lay consumers participated.
- Data Provenance: Not explicitly stated, but the submission is from a Taiwanese company (BIONIME CORPORATION NO 694, RENHUA ROAD, DALI DIST., TAICHUNG CITY, TAIWAN 412), suggesting the studies may have been conducted in Taiwan or a related region. It does not specify if the data was retrospective or prospective, but clinical studies are generally prospective.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
- Number of Experts: Not explicitly stated.
- Qualifications of Experts: Not explicitly stated. The ground truth for the accuracy study was established by "plasma glucose values on a lab instrument," implying trained laboratory personnel were involved, but their specific qualifications are not detailed.
4. Adjudication Method for the Test Set
- The text does not mention an adjudication method (such as 2+1 or 3+1) for establishing the ground truth. The ground truth was based on a "lab instrument" for plasma glucose values.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done
- No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. This study is focused on the performance of a medical device (blood glucose monitor), not an AI algorithm assisting human readers.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done
- This question is not applicable as the device is a Blood Glucose Monitoring System, which includes the meter, test strips, and control solution, and is used by a human. The "standalone" concept typically applies to AI algorithms. The system itself is the "standalone" diagnostic tool.
7. The Type of Ground Truth Used
- Type of Ground Truth: The ground truth for the system accuracy study was established using "plasma glucose values on a lab instrument." This is a reference measurement, often considered a highly accurate and standardized method for glucose determination.
8. The Sample Size for the Training Set
- Blood Glucose Monitoring Systems are typically developed through electrochemical and hardware engineering, and thus do not involve a "training set" in the context of machine learning. Therefore, a sample size for a training set is not applicable to this device.
9. How the Ground Truth for the Training Set Was Established
- As the concept of a "training set" is not applicable to the development of this device, the question of how its ground truth was established is not applicable. Device performance is validated against established laboratory reference methods and clinical accuracy standards, rather than "training" an algorithm.
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.